Effects of rTMS on Respiratory Function and Gut Microbiota in Patients With Brain Injury

Nanfang Hospital, Southern Medical University

Status

Not yet enrolling

Conditions

Brain Injuries

Respiratory Function Impaired

Gut Microbiota

Treatments

Device: sham rTMS

Device: active rTMS

Study type

Interventional

Funder types

Other

Identifiers

NCT06288984

NFEC-2024-061

Details and patient eligibility

About

Impaired respiratory function may occur after brain injury, and will progress to restricted respiratory dysfunction without early intervention. At present, there is a lack of effective treatment options for respiratory dysfunction. Repetitive Transcranial Magnetic Stimulation(rTMS) is a non-invasive, painless and non-invasive neuroregulatory technique. In healthy people, rTMS applied to the respiratory motor cortex induces a contralateral respiratory muscle response. However, whether rTMS can improve respiratory function in patients with brain injury remains unclear. gut microbiota can affect muscle function and mass, and animal experiments have shown that probiotics can increase skeletal muscle mass and grip strength in mice. On the other hand, studies have found that rTMS can improve the nutritional status of patients with vegetative state by regulating the structure of gut microbiota. However, it remains unclear whether rTMS can improve respiratory muscle function in patients with brain injury by regulating gut microbiota. Therefore, the investigators intend to apply rTMS to the respiratory motor cortex to observe whether rTMS can improve respiratory function and reduce the incidence of pneumonia in patients with brain injury, and to observe the role of gut microbiota in this process.

Enrollment

74 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

In line with the diagnostic criteria of "Chinese classification of cerebrovascular diseases(2015)" mRS Score 2-4 points or craniocerebral injury caused by trauma, GCS score > 8 points
Between 18 and 70 years old
The first incidence of cerebrovascular disease or traumatic brain injury, and the course of disease was 10-180 days
Vital signs are stable, no progression
Voluntary participation with informed consent

Exclusion criteria

Patients with a history of respiratory disease, including chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, and lung cancer
Severe bone malformations in the chest or spine
Have other neurological or neuromuscular disorders
History of thoracic and abdominal surgery
Severe heart, lung, kidney, liver or other organ dysfunction
Pregnant and lactating women
Epilepsy
Metal implant
Patients who were judged by the investigator to be unsuitable for participation in this trial